We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Mar 2018
  • Code : CMI1373
  • Industry : Pharmaceutical
  • Pages : 180
  • Formats :

Alzheimer’s Drugs Market - Young Prospect for Aging Patient

Alzheimer’s is a form of dementia, which affect behavior, thinking, and memory of patient. The progression of disease is slow and it degrades neurons associated with learning part of cerebrum. It is most common and largest form of dementia (more than 60%), which is observed in people of age 65 and above. Accumulation of protein called as beta amyloid in spaces between nerve cells due to genetic mutation is major cause of Alzheimer. Although Alzheimer’s disease is not treatable, symptomatic treatment is followed in all cases. Research is being carried out to develop treatment centered on the role of beta-amyloid in Alzheimer’s disease.

The global Alzheimer’s drugs market was valued at US$ 7 billion in 2016 and is expected to witness a CAGR of 9.5% over the forecast period (2017 - 2025).

Figure 1. Global Alzheimer’s Drugs Market (US$ Bn), by Region, 2016

alzheimer's drugs market

Source: Coherent Market Insights

Increasing prevalence of Alzheimer’s disease to drive growth of the Alzheimer’s drugs market worldwide

Increasing prevalence and incidence of Alzheimer’s disease worldwide is expected to drive the growth of Alzheimer’s disease therapeutics market. According to World Alzheimer Report in 2016, an estimated 46.5 million people were suffering from Alzheimer’s disease and the number is projected to reach 50 million by 2017, every three second there is new patient of Alzheimer’s disease worldwide.

Increasing age and aging global population are major risk factors for Alzheimer’s, which increase the disease incidence and provide growth opportunity for Alzheimer’s treatment market. For instance, according to World Population Prospects (WPP) published by United Nations in 2017, an estimated 962 million people are of age 60 or above, which accounted for 13 per cent of the global population. The number is projected to reach 1.4 billion by 2030, growing with annual rate of 3 percent. Europe currently has highest geriatric population (25% of population), Asia Pacific had geriatric population of 547 million people and it is projected to reach 900 million by 2025, therefore these regions have potential opportunity for growth of the market. India has more than 1 million cases of Alzheimer’s disease annually. North America holds dominant position in the Alzheimer’s disease therapeutics market with estimated 5.5. Mn patients in 2017. The robust healthcare infrastructure in the region, and the region being an early adopter of novel technologies, positions it as a major market for Alzheimer’s disease.

Large number of undiagnosed patient’s and revised diagnostic guidelines to propel growth for Alzheimer’s drugs market

People suffering from early stage of Alzheimer’s disease with some dementia do not have appropriate access to the healthcare infrastructure to diagnose and treat the disease. For instance according to World Alzheimer Report in 2016, only around 50% patients suffering from dementia undergo diagnosis. The rate of underdiagnoses is 10% in low and middle income economies, therefore, this is expected to propel growth of Alzheimer’s drugs market. As of 2011, there were no standard guidelines for diagnosis of disease. Currently, biomarker tests involving amount of beta-amyloid in the brain, which can be visualized in positron emission tomography imaging are under research to diagnosis develop treatment for Alzheimer’s disease. Currently, there is no curative therapy available for Alzheimer’s disease. However, drugs for Alzheimer’s therapy are in pipeline, which are expected to launch in near future, which in turn is propelling growth of Alzheimer’s disease therapeutics market.

Key players operating in Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd., Other prominent players whose products are under clinical trials are Eli Lilly and Company, TauRx Pharmaceuticals Ltd, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune.

The Alzheimer’s disease is one of the most prevalent neurodegenerative disease, which is associated proportionately with increased life expectancy worldwide. Patient suffers and encounters various behavioral change with dementia, as a primary symptoms, which gets worse as disease progress. It majorly affects people of age group 65 and above. Currently, there is no therapeutic cure available for Alzheimer’s disease, however, available drugs can lower symptoms or severity of the disease. Although many companies have invested in the development of new drug for Alzheimer’s disease, a very few molecules have shown a steady improvement in condition of patient and many of those investigational candidates failed to provide significant improvement in patients condition during phase three clinical trials.

Market Dynamics

Major factor fueling growth of the Alzheimer’s drugs market is large number of drugs in pipeline, which are expected to enter into market by 2022. According to the study published by Translational Research and Clinical Intervention in September 2017, there are 105 new drugs in pipeline, out of which 25 are in phase one, 52 in phase two and 28 are in phase three. These new products has novel approach such as immunotherapy to target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, serotonin 5-HT6 receptor antagonist. Along with this there is an increase amount of collaboration amongst companies for developing drugs in joint effort, for instance in November 2017, Novartis and Amgen, along with the Banner Alzheimer's Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to  prevent or delay symptoms of Alzheimer's disease. In 2016, AstraZeneca and Eli Lilly and Company entered into worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials, as a potential disease-modifying treatment for Alzheimer’s disease. These collaborations are expected to accelerate the development process and bring efficiency in entire arena of operations. However, failing of investigational candidate in late stage is expected to be a huge setback in the current Alzheimer’s drugs market, for instance in February 2017, an external data monitoring committee warned that Merck & Co. terminated study of Alzheimer's candidate verubecestat due to potential failure in a Phase II/III study.

Key features of the study:

  • This report provides in-depth analysis of Alzheimer’s drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global Alzheimer’s drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global Alzheimer’s drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Alzheimer’s drugs market

Detailed Segmentation:

  • Global Alzheimer’s Drugs Market, By Drugs:
    • Donepezil
    • Rivastigmine
    • Galantamine
    • Memantine
  • Global Alzheimer’s Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • e-Commerce
  • Global Alzheimer’s Drugs Market, By Geography:
    • North America
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drugs:
        • Donepezil
        • Rivastigmine
        • Galantamine
        • Memantine
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments
      • Key Strategies
    • Janssen Pharmaceuticals
    • Novartis International AG
    • Eisai Co. Ltd
    • Lundbeck A/S
    • Teva Pharmaceuticals Industries Ltd
    • Daichi Sankyo Company Limited

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global Alzheimer’s drugs market is estimated to surpass US$ 15 Billion by 2025.
Major players operating in the global Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd., Other prominent players whose products are under clinical trials are Eli Lilly and Company, TauRx Pharmaceuticals Ltd, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune.
Increasing prevalence and incidence of Alzheimer’s disease worldwide is one of the major factors that is influencing the adoption of Alzheimer’s drugs globally.
Rising prevalence and incidence of Alzheimer’s disease globally, coupled with improved diagnostics and development of novel drugs are some of the major factors that are expected to propel growth of the market over the forecast period.
The global Alzheimer’s drugs market is estimated to exhibit a CAGR of 9.5% over the forecast period.
Among regions, North America held dominant position in the global Alzheimer’s drugs market in 2016.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo